Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) See
Post# of 62
(Total Views: 372)
Posted On: 01/04/2019 6:15:41 PM
Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) Sees Opportunity in Applying Novel Skin Remedies to Health Concerns
- Therma Bright’s thermal, dermatological technologies finding value in responding to array of concerns, from pain to pandemics
- Wider cosmeceutical industry expected to grow at CAGR of 8.21 percent between 2017 and 2023
- Therma Bright’s niche focus is in strengthening skin defenses through non-invasive infrared energy and cannabidiol properties
Skin health is a critical component of a person’s overall wellness, and the researchers at Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) are making dermatological defenses the first line of resistance against a variety of medical concerns ranging from pain to pandemics.
The medical device developer has been an innovator in the field of using infrared light to tackle skin maladies by delivering controlled topical heat to afflicted areas without a risk of burning the skin. The technology was introduced as the trademarked InterceptCS product to treat cold sores by killing cells infected with the herpes simplex Type 1 virus. Design and engineering of the system was completed in late 2005 and in April 2006 (http://nnw.fm/0ZIUw).*
More recently, the company has been advancing its TherOZap technology as a first-generation medical device approved by the U.S. Food and Drug Administration (FDA) for the relief of the symptoms of skin pain, itch and inflammation associated with insect bites and stings. Therma Bright has been working on a TherOZap product that may provide a skin barrier to combat the Zika virus and other mosquito-borne diseases such as dengue, and it recently announced that final prototypes were sent to a research laboratory where testing of the technology against the Zika virus is underway (http://nnw.fm/46uM0).
Zika gained worldwide attention after an outbreak in 2015, and its apparent connection to Latin American children’s birth defects, such as the brain-damaging microcephaly head ailment, led the World Health Organization to declare the sexually transmitted virus a “Public Health Emergency of International Concern” because of its high potential for transnational transmission to other parts of the world (http://nnw.fm/tC77N).
Dengue has been making news for decades as a viral infectious disease originating, like Zika, from mosquito bites. It used to be called “break-bone fever” because it sometimes causes severe joint and muscle pain that feels like bones are breaking. WHO estimates that there may be 50-100 million dengue cases around the world every year, although some analysts believe the number is higher (http://nnw.fm/TV4Kw).
Researchers have been reporting progress lately toward potential vaccines. Clinical trials are underway for Zika solutions (http://nnw.fm/vEoj5), and a partial dengue vaccine became commercially available in 11 countries in 2016 amid ongoing concerns about adverse responses in some vaccinated populations (http://nnw.fm/dA8cR).
Therma Bright’s novel barrier solution could provide a welcome response to medical concerns on a worldwide scale. The Zika trials are expected to last several months, an indication of their importance.
In October, Therma Bright revealed that it is also developing testing for a hemp cannabidiol (CBD)-based pain relief therapy that will use creams, gels or salves in concert with its thermal-generation products to target various forms of general or chronic pain such as back pain, arthritic pain and other orthopedic concerns. The company announced its first prototype in December.
Therma Bright’s attention to such a variety of skin care concerns positions it well within the cosmeceuticals market, which is expected to grow at a CAGR of 8.21 percent between 2017 and 2023, resulting in a worldwide market valued at $72.99 billion overall (http://nnw.fm/k91bY).
For more information, visit the company’s website at www.ThermaBright.com
* Based on double blind placebo study the InterceptCS™ is approved for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” by Health Canada. The InterceptCS™ is not approved by the United States FDA for any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Therma Bright’s thermal, dermatological technologies finding value in responding to array of concerns, from pain to pandemics
- Wider cosmeceutical industry expected to grow at CAGR of 8.21 percent between 2017 and 2023
- Therma Bright’s niche focus is in strengthening skin defenses through non-invasive infrared energy and cannabidiol properties
Skin health is a critical component of a person’s overall wellness, and the researchers at Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) are making dermatological defenses the first line of resistance against a variety of medical concerns ranging from pain to pandemics.
The medical device developer has been an innovator in the field of using infrared light to tackle skin maladies by delivering controlled topical heat to afflicted areas without a risk of burning the skin. The technology was introduced as the trademarked InterceptCS product to treat cold sores by killing cells infected with the herpes simplex Type 1 virus. Design and engineering of the system was completed in late 2005 and in April 2006 (http://nnw.fm/0ZIUw).*
More recently, the company has been advancing its TherOZap technology as a first-generation medical device approved by the U.S. Food and Drug Administration (FDA) for the relief of the symptoms of skin pain, itch and inflammation associated with insect bites and stings. Therma Bright has been working on a TherOZap product that may provide a skin barrier to combat the Zika virus and other mosquito-borne diseases such as dengue, and it recently announced that final prototypes were sent to a research laboratory where testing of the technology against the Zika virus is underway (http://nnw.fm/46uM0).
Zika gained worldwide attention after an outbreak in 2015, and its apparent connection to Latin American children’s birth defects, such as the brain-damaging microcephaly head ailment, led the World Health Organization to declare the sexually transmitted virus a “Public Health Emergency of International Concern” because of its high potential for transnational transmission to other parts of the world (http://nnw.fm/tC77N).
Dengue has been making news for decades as a viral infectious disease originating, like Zika, from mosquito bites. It used to be called “break-bone fever” because it sometimes causes severe joint and muscle pain that feels like bones are breaking. WHO estimates that there may be 50-100 million dengue cases around the world every year, although some analysts believe the number is higher (http://nnw.fm/TV4Kw).
Researchers have been reporting progress lately toward potential vaccines. Clinical trials are underway for Zika solutions (http://nnw.fm/vEoj5), and a partial dengue vaccine became commercially available in 11 countries in 2016 amid ongoing concerns about adverse responses in some vaccinated populations (http://nnw.fm/dA8cR).
Therma Bright’s novel barrier solution could provide a welcome response to medical concerns on a worldwide scale. The Zika trials are expected to last several months, an indication of their importance.
In October, Therma Bright revealed that it is also developing testing for a hemp cannabidiol (CBD)-based pain relief therapy that will use creams, gels or salves in concert with its thermal-generation products to target various forms of general or chronic pain such as back pain, arthritic pain and other orthopedic concerns. The company announced its first prototype in December.
Therma Bright’s attention to such a variety of skin care concerns positions it well within the cosmeceuticals market, which is expected to grow at a CAGR of 8.21 percent between 2017 and 2023, resulting in a worldwide market valued at $72.99 billion overall (http://nnw.fm/k91bY).
For more information, visit the company’s website at www.ThermaBright.com
* Based on double blind placebo study the InterceptCS™ is approved for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” by Health Canada. The InterceptCS™ is not approved by the United States FDA for any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)